Loading…
← CockpitCompetitor Analysis › PBYI Puma Biotechnology, Inc.Open in the cockpit ↗

Puma Biotechnology, Inc.PBYICompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 27
Mkt cap
$373M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$4.48M
20-day average traded
Fwd P/E
19.0×
forward earnings
ROIC−WACC
+36.2 pp
WACC 11.9%
Hurdle
-0 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$7.22
1D+1.1%
1W-10.6%
1M-32.9%
3M-20.8%
6M+3.3%
YTD+21.3%
1Y+45.6%
ATR %7.1%
Beta0.98
52w lowhigh37.2% off high

What Puma Biotechnology does

Employees: 179

Puma Biotechnology at a glance

Size Puma Biotechnology (PBYI) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $373M, the 2895th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.22 on 18 Nov 2026.

Performance Over six months the shares gained 3.3%, against -25.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 9.3% over the last twelve months (peer median -6.5%); the operating margin is 11.3% (peer median -7.8%).

Valuation It trades at 19.0× forward earnings against a peer median of 24.5× (3rd cheapest of 5).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 36.2 points above its cost of capital (11.9% WACC).

Short interest Short interest is 8.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026PBYI 102Peer median 75
Six months, rebased to 100: Puma Biotechnology against the median of its 20 peers (local-currency closes).

Puma Biotechnology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$232M$228M$230M$236M$228M
Revenue growth—-1%-2%+3%—
Gross profit$171M$170M$166M$173M$173M
EBITDA$36.2M$48.2M$42.5M$44.8M$39.6M
Net income$23.8M$31.1M$30.3M$21.6M$2,000
Free cash flow$46.1M$41.7M$38.9M$26.9M-$15.8M
Capital expenditure-$36,000$71,000$56,000$12.6M$0
Total debt$4.87M$28.5M$74.1M$111M$114M

Quarterly statements and history in the cockpit →

Puma Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-40%-20%0%688399SPRY002872MPLT301111IRD45520056903010894592UNICHEMLAB30053442C4569AVTX300452000153PBYI6-month return →1-month return →
Up and to the right = strong over both horizons. Puma Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×45520056904569300452PBYIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Puma Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%0028720056903005344569300452000153PBYIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Puma Biotechnology is the large dot.

Puma Biotechnology competitors and peer comparison

How Puma Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Puma Biotechnology against its 20 peers (data as of 18 Nov 2026)
MeasurePBYIPeer medianRank in peer set
1-month return-32.9%-13.3%2nd lowest of 20
6-month return+3.3%-25.1%3rd highest of 19
Distance from 52-week high-37.2%-43.3%10th highest of 21
Revenue growth (TTM)+9.3%-6.5%4th highest of 18
Operating margin11.3%-7.8%4th highest of 19
Forward P/E19.0×24.5×3rd cheapest of 5
Growth the price implies (Req g, 7 yrs)0.1%5.1%3rd least demanding of 7
Growth delivered (Del g)+0.3%+8.2%2nd lowest of 7
Hurdle (Req g minus delivered)-0.2 pp-3.4 pp4th least demanding of 7
ROIC minus cost of capital+36.2 pp-6.9 pphighest of 17
EV / EBITDA7.4×15.7×cheapest of 6
Net debt / EBITDA-2.9×0.2×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Puma Biotechnology PBYIUnited States$373M+3%+9%11%19.0×0.1%+0.3%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%n/an/an/a
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%n/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%n/a22.2%-15.7%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%n/an/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%n/an/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%n/an/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%398.3×n/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%8.2×-7.9%+24.8%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%n/an/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%n/an/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%n/a20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%n/an/an/a
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%35.5×6.7%+4.2%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%13.6×-5.5%+12.2%
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%n/a3.6%+3.1%

Questions

Which companies are Puma Biotechnology's closest peers?
The cockpit's peer set: Jiangsu Bioperfectus Technologies (688399.SS), ARS Pharmaceuticals (SPRY), Tiansheng Pharmaceutical (002872.SZ), MapLight Therapeutics (MPLT), 6467 (6467.TW), Guangdong Lifestrong Pharmacy (301111.SZ), Opus Genetics (IRD), JCR Pharmaceuticals (4552.T).
Is Puma Biotechnology expensive compared with its peers?
On forward p/e it trades at 19.0× against a peer median of 24.5×, 3rd cheapest of 5 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Puma Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned +3.3% against -25.1% for the median peer; over one year +45.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.